<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000759.v1.p1" parentStudy="phs000759.v1.p1" createDate="2014-06-12" modDate="2014-10-07">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Kevin White, PhD</td><td>University of Chicago, Chicago, IL, USA</td></tr>
		<tr><td>Co-Investigator</td><td>Megan McNerney, MD, PhD</td><td>University of Chicago, Chicago, IL, USA</td></tr>
		<tr><td>Funding Source</td><td>P01 CA040046</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		<tr><td>Funding Source</td><td>Chicago Cancer Genomes Project</td><td>University of Chicago, Chicago, IL, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Spectrum of Mutations in Myeloid Neoplasms</StudyNameEntrez>
	<StudyNameReportPage>The spectrum of somatic mutations in high-risk acute myeloid leukemia with -7/del(7q)</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Tumor vs. Matched-Normal</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Patients with myeloid malignancies bearing high-risk cytogenetic abnormalities lack effective therapies and have a poor overall survival. -7/del(7q) is identified in half of high-risk myeloid neoplasms. We recently identified <i>CUX1</i> to be a haploinsufficient myeloid tumor suppressor gene located within the commonly deleted segment of 7q22. Here we identify the spectrum of somatic mutations that co-occur with loss of <i>CUX1</i> and chromosome 7 in patients with <i>de novo</i> acute myeloid leukemia (AML) or a therapy-related myeloid neoplasm. -7/del(7q) leukemias have a distinct mutational profile characterized by low frequencies of alterations in major leukemogenic pathways, including genes encoding transcription factors, cohesin, and DNA-methylation-related proteins. In contrast, RAS pathway activating mutations occurred in 40% of -7/del(7q) samples, a significantly higher frequency than other AMLs and higher than previously reported. As targeted therapeutics advance, our data provide guidance for which pathways are most relevant in the treatment of adverse-risk myeloid leukemia. </p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="24931631"/>
		</Publication>
		<Publication>
			<Pubmed pmid="25043302"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Leukemia, Myeloid, Acute"/>
		<Disease vocab_source="MESH" vocab_term="Neoplasm, therapy related"/>
		<Disease vocab_source="MESH" vocab_term="Monosomy 7"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Kevin White, PhD</AttName>
			<Institution>University of Chicago, Chicago, IL, USA</Institution>
		</Header>
		<Header title="Co-Investigator">
			<AttName>Megan McNerney, MD, PhD</AttName>
			<Institution>University of Chicago, Chicago, IL, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>P01 CA040046</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Chicago Cancer Genomes Project</AttName>
			<Institution>University of Chicago, Chicago, IL, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU-MDS" longName="General Research Use (MDS)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000759.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000759.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000759.v1.p1" FileName="eNCI_0197_DUC_6.9.2014.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use (MDS)</ConsentName>
        <ConsentAbbrev>GRU-MDS</ConsentAbbrev>
        <UseLimitation>Use of the data is limited only by the terms of the model Data Use Certification.
Use of the data includes methods development research (e.g., development of software or algorithms).</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
